Abstract
Caprolactam urea 1, identified as a weak Factor Xa inhibitor screening hit (IC50 = 16 μM), served as the starting point for a limited parallel-synthesis driven SAR study to improve potency. Remarkably, the corresponding thiourea analog 8c (IC50 = 0.11 μM) was 145-fold more potent against Factor Xa compared to 1. In general, caprolactam analogs containing a thiourea linker were significantly more potent than their corresponding urea counterparts, and it is hypothesized that this is partly due to a conformational preference of the thiourea linkage which facilitates binding of the terminal groups of the inhibitors to the Factor Xa S1/S4 pockets. Analog 8c was selective against a panel of related serine proteases. Upon intra-duodenal administration in rats, 8c dose-dependently increased prothrombin time ex vivo, and when dosed i.v., it demonstrated efficacy in a rat model of venous thrombosis. This thiourea lead series formed the basis for follow-on investigations to discover potent drug-like Factor Xa inhibitors using the caprolactam scaffold but employing suitable thiourea surrogates.
Keywords: Factor Xa, FXa inhibitor, caprolactam, serine protease
Letters in Drug Design & Discovery
Title: Initial Structure-Activity Relationships for a Caprolactam-based Series of Neutral Factor Xa Inhibitors: Lead Identification
Volume: 2 Issue: 8
Author(s): Gregory S. Bisacchi, Philip D. Stein, Jack Z. Gougoutas, Karen S. Hartl, R. Michael Lawrence, Eddie Liu, Andrew Pudzianowski, William A. Schumacher, Doree Sitkoff, Thomas E. Steinbacher, James Sutton, Zhaoxiao Zhang and Steven M. Seiler
Affiliation:
Keywords: Factor Xa, FXa inhibitor, caprolactam, serine protease
Abstract: Caprolactam urea 1, identified as a weak Factor Xa inhibitor screening hit (IC50 = 16 μM), served as the starting point for a limited parallel-synthesis driven SAR study to improve potency. Remarkably, the corresponding thiourea analog 8c (IC50 = 0.11 μM) was 145-fold more potent against Factor Xa compared to 1. In general, caprolactam analogs containing a thiourea linker were significantly more potent than their corresponding urea counterparts, and it is hypothesized that this is partly due to a conformational preference of the thiourea linkage which facilitates binding of the terminal groups of the inhibitors to the Factor Xa S1/S4 pockets. Analog 8c was selective against a panel of related serine proteases. Upon intra-duodenal administration in rats, 8c dose-dependently increased prothrombin time ex vivo, and when dosed i.v., it demonstrated efficacy in a rat model of venous thrombosis. This thiourea lead series formed the basis for follow-on investigations to discover potent drug-like Factor Xa inhibitors using the caprolactam scaffold but employing suitable thiourea surrogates.
Export Options
About this article
Cite this article as:
Bisacchi S. Gregory, Stein D. Philip, Gougoutas Z. Jack, Hartl S. Karen, Lawrence Michael R., Liu Eddie, Pudzianowski Andrew, Schumacher A. William, Sitkoff Doree, Steinbacher E. Thomas, Sutton James, Zhang Zhaoxiao and M. Seiler Steven, Initial Structure-Activity Relationships for a Caprolactam-based Series of Neutral Factor Xa Inhibitors: Lead Identification, Letters in Drug Design & Discovery 2005; 2 (8) . https://dx.doi.org/10.2174/157018005774717316
DOI https://dx.doi.org/10.2174/157018005774717316 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pyrrolo[2,3-d]Pyrimidines as Kinase Inhibitors
Current Medicinal Chemistry Current Advancements in Aβ Luminescent Probes and Inhibitors of Aβ Aggregation
Current Alzheimer Research Synthesis and Anticancer Activity of Some 2-[3/4-(2-Substituted Phenyl-2- oxoethoxy)benzylidene]-6-substituted-2,3-dihydro-1H-inden-1-one Derivatives
Letters in Drug Design & Discovery Withdrawal Notice: The Relationship between Opium Use and Coronavirus Infection: A Brief Research Report from Iran
Coronaviruses Artificial Intelligence in Pharmacovigilance and COVID-19
Current Drug Safety Synthesis and Biological Evaluation of 3-Chloro-4-(indol-3-yl)-2,5- pyrroledione Derivatives as Antitumor Agents
Letters in Drug Design & Discovery Targeting of Hsp32 in Solid Tumors and Leukemias: A Novel Approach to Optimize Anticancer Therapy (Supplementry Material)
Current Cancer Drug Targets Secretoneurin: A New Player in Angiogenesis and Chemotaxis Linking Nerves, Blood Vessels and the Immune System
Current Protein & Peptide Science Fibrocytes in the Pathogenesis of Chronic Fibrotic Lung Disease
Current Respiratory Medicine Reviews Chemotopology: Beyond Neighbourhoods
Current Computer-Aided Drug Design Plant Phenolic Compounds as Potential Lead Compounds in Functional Foods for Antiviral Drug Discovery
Current Organic Chemistry Discovery of Camptothecin Based Topoisomerase I Inhibitors: Identification Using an Atom Based 3D-QSAR, Pharmacophore Modeling, Virtual Screening and Molecular Docking Approach
Combinatorial Chemistry & High Throughput Screening Development of Plasmodium falciparum Protease Inhibitors in the Past Decade (2002–2012)
Current Medicinal Chemistry Recent Advances in the Application of Podophyllotoxin Derivatives to Fight Against Multidrug-Resistant Cancer Cells
Current Topics in Medicinal Chemistry Design, Synthesis and Structure-Activity Relationship Studies of Novel 4 (1-adamantyl) Phenyl Analogues as HIF-1α Inhibitors
Medicinal Chemistry Combination Therapy for the Treatment of Alzheimer’s Disease: Recent Progress and Future Prospects
Current Topics in Medicinal Chemistry Quinoline – a Promising Fragment in the Search for New Antimalarials
Mini-Reviews in Medicinal Chemistry <i>De Novo</i> Vasculitis after COVID-19 Vaccination
Current Rheumatology Reviews Reactive Oxygen Species, Vascular Disease and Cardiovascular Surgery
Current Vascular Pharmacology Pharmacological Regulators of Intracellular Calcium Release Channels
Current Pharmaceutical Design